Featured Research

from universities, journals, and other organizations

Cancer drug target is promising lead for new TB treatments

Date:
November 17, 2010
Source:
Society for General Microbiology
Summary:
A key enzyme in Mycobacterium tuberculosis that enables the microbe to reproduce rapidly could be a golden target for new drugs against tuberculosis, according to a new study. The human equivalent of this enzyme has been targeted in some cancer treatments as well as in immunosuppressive chemotherapies. Scientists have now shown that inhibiting the same enzyme in M. tuberculosis effectively kills the bacterial cells.

A key enzyme in Mycobacterium tuberculosis that enables the microbe to reproduce rapidly could be a golden target for new drugs against tuberculosis (TB), according to a study published in Microbiology on 17 November.

Related Articles


The human equivalent of this enzyme has been targeted in some cancer treatments as well as in immunosuppressive chemotherapies. Scientists at the University of Birmingham have now shown that inhibiting the same enzyme in M. tuberculosis effectively kills the bacterial cells.

The enzyme called IMPDH is crucial for the survival of both human and bacterial cells. It is involved in the first stage of producing guanine nucleotides -the raw materials needed for DNA synthesis -- as well as many other housekeeping processes that keep the cell alive and functioning.

The researchers identified the three genes in M. tuberculosis that encode IMPDH and then screened a library of 16 compounds that were likely to impede its function to some extent. Of the 16 diphenyl urea (DPU) compounds, 3 were able to inhibit IMPDH by more than 90%, killing M. tuberculosis cells.

Project leader Professor Gurdyal Besra explained why IMPDH is a promising target to tackle TB. "IMPDH is essential for cells to proliferate rapidly, which is one of the characteristics of microbial infection as well as human cancers. IMPDH has been used as a target in some anti-cancer drugs, as blocking the enzyme can prevent proliferation of the cell and induce cell death. Our findings show that inhibiting the bacterial version of IMPDH is a strategy that could be exploited for anti-TB drugs," he said. "The DPU compounds we tested have selective activity against Mycobacterium species, meaning that any future drugs based on these would be specific and would not affect human cells."

9 million people are newly diagnosed with TB each year with increasing incidences of multi-drug resistant (MDR)-TB and extensively drug resistant (XDR)-TB. "In the face of growing resistance to current therapies, we desperately need new treatments for TB that are safe and effective," stressed Professor Besra. "We are tapping the potential of a so far unexploited target which could lead to the synthesis of a novel anti-tubercular drug and our findings, so far are extremely encouraging," he said.


Story Source:

The above story is based on materials provided by Society for General Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Veeraraghavan Usha, Sudagar S Gurcha, Andrew Lovering, Adrian J Lloyd, Athina Papaemmanouil, Robert C Reynolds and Gurdyal S Besra. Identification of novel diphenyl urea inhibitors of Mt-Guab2 active against Mycobacterium tuberculosis. Microbiology, 16 November 2010 DOI: 10.1099/mic.0.042549-0

Cite This Page:

Society for General Microbiology. "Cancer drug target is promising lead for new TB treatments." ScienceDaily. ScienceDaily, 17 November 2010. <www.sciencedaily.com/releases/2010/11/101116203436.htm>.
Society for General Microbiology. (2010, November 17). Cancer drug target is promising lead for new TB treatments. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2010/11/101116203436.htm
Society for General Microbiology. "Cancer drug target is promising lead for new TB treatments." ScienceDaily. www.sciencedaily.com/releases/2010/11/101116203436.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins